Immunic, Inc. Share Price & Technical Analysis
IMUX · $12.06 (-5.56%)
Healthcare / Biotechnology
$12.06
-5.56%
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative …
Price chart
Seasonality
Jun has 2 positive and 3 negative years (last 5 years shown)
-20% return in Jun, 14% avg return in past 3 year Jun month.
109% return in 2026, -12% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 11% | 65% | 12% | -15% | 56% | -20% | – | – | – | – | – | – | 109% |
| 25 | -7% | 27% | -10% | -12% | -35% | 3% | 31% | -9% | 7% | -10% | -9% | -25% | -50% |
| 24 | -20% | 21% | -9% | -6% | -4% | -11% | 27% | 7% | 9% | -27% | 2% | -20% | -31% |
| 23 | 67% | -17% | -25% | 14% | -1% | 49% | -7% | -30% | -12% | -28% | 11% | 24% | 43% |
| 22 | 22% | -2% | -3% | -40% | -7% | -44% | 2% | 27% | -28% | -45% | -24% | 4% | -138% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Uptrend · Neutral
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$169.04M
P/E ratio
—
52W high
$15.77
52W low
$5.06
Volume
2,01,656
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Immunic, Inc. share price today?
- Immunic, Inc. (IMUX) last traded around $12.06 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IMUX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IMUX. Download the app for real-time alerts.
- How can I analyze Immunic, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.